)
)
)
CARsgen Therapeutics
CARsgen (HKEX 02171), founded in 2014, is a commercial-stage biopharmaceutical company operating in China and the U.S, listed in Hong Kong since 2021. Driven by the vision of making cancer curable, CARsgen has developed a suite of differentiated technology platforms, diversified product pipeline, and end-to-end capabilities.
CARsgen has developed a rich product pipeline
1) Autologous CAR-T: BCMA CAR-T (approved), CLDN18.2 CAR-T (under NDA review)
2) Allogeneic CAR-T: BCMA (IIT stage), CD19/CD20 (IIT stage), CD38, NKG2DL, etc
3) Fully-human/humanized CAR constructs
- BCMA; GPRC5D, CLDN18.2, GPC3, etc
- Dual CARs (BCMA/GPCRC5D, CD19/CD20, CD19/BCMA, etc)
We are open to the licensing/co-development collaborations for ex vivo and in vivo CAR-T assets.
Address
ShanghaiChina
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)